Similar articles

• Frequency and outcomes of provisional glycoprotein IIb/IIIa blockade in patients receiving bivalirudin during percutaneous coronary intervention.

  Feldman DN, Wong SC, Bergman G, Minutello RM. Feldman DN, et al. J Invasive Cardiol. 2009 Jun;21(6):258-63. J Invasive Cardiol. 2009. PMID: 19494400
• A comparison of abciximab and small-molecule glycoprotein IIb/IIIa inhibitors in patients undergoing primary percutaneous coronary intervention: a meta-analysis of contemporary randomized controlled trials.

  Gurm HS, Tamhane U, Meier P, Grossman PM, Chetcuti S, Bates ER. Gurm HS, et al. Circ Cardiovasc Interv. 2009 Jun;2(3):230-6. doi: 10.1161/CIRCINTERVENTIONS.108.847996. Epub 2009 Apr 21. Circ Cardiovasc Interv. 2009. PMID: 20031720
• Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial.

  Lincoff AM, Kleiman NS, Kereiakes DJ, Feit F, Bittl JA, Jackman JD, Sarembock IJ, Cohen DJ, Spriggs D, Ebrahimi R, Keren G, Carr J, Cohen EA, Betriu A, Desmet W, Rutsch W, Wilcox RG, de Feyter PJ, Vahanian A, Topol EJ; REPLACE-2 Investigators. Lincoff AM, et al. JAMA. 2004 Aug 11;292(6):696-703. doi: 10.1001/jama.292.6.696. JAMA. 2004. PMID: 15304466 Clinical Trial.
• Contemporary use of antiplatelet therapies in percutaneous coronary interventions.

  Saw J, Moliterno DJ. Saw J, et al. Coron Artery Dis. 2003 Aug;14(5):373-80. doi: 10.1097/01.mca.0000085946.79284.75. Coron Artery Dis. 2003. PMID: 12878902 Review. No abstract available.
• Should glycoprotein IIb/IIIa inhibitors be used during all percutaneous coronary interventions? No.

  Ragosta M, Sarembock IJ. Ragosta M, et al. J Thromb Haemost. 2004 Jan;2(1):10-2. doi: 10.1111/j.1538-7836.2004.00560.x. J Thromb Haemost. 2004. PMID: 14717959 Review. No abstract available.